The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Adalimumab Monoclonal Antibody Biosimilar Market Research Report 2024

Global Adalimumab Monoclonal Antibody Biosimilar Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1739054

No of Pages : 94

Ask Your Query

Synopsis
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

Global Adalimumab Monoclonal Antibody Biosimilar market is projected to reach US$ 958.9 million in 2029, increasing from US$ 421 million in 2022, with the CAGR of 12.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adalimumab Monoclonal Antibody Biosimilar market research.

The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adalimumab Monoclonal Antibody Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Cadila Healthcare
  • Torrent Pharmaceuticals
  • Amgen
  • Boehringer Ingelheim
  • Novartis
  • Samsung Bioepis
  • Viatris
  • Pfizer
  • Fresenius Kabi
  • Coherus

Segment by Type

  • Syringe
  • Pen

Segment by Application

  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Adalimumab Monoclonal Antibody Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Adalimumab Monoclonal Antibody Biosimilar Market Overview
1.1 Product Overview and Scope of Adalimumab Monoclonal Antibody Biosimilar
1.2 Adalimumab Monoclonal Antibody Biosimilar Segment by Type
1.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Syringe
1.2.3 Pen
1.3 Adalimumab Monoclonal Antibody Biosimilar Segment by Application
1.3.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Value by Application: (2023-2029)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Adalimumab Monoclonal Antibody Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue 2018-2029
1.4.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales 2018-2029
1.4.3 Global Adalimumab Monoclonal Antibody Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Adalimumab Monoclonal Antibody Biosimilar Market Competition by Manufacturers
2.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Adalimumab Monoclonal Antibody Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab Monoclonal Antibody Biosimilar, Product Type & Application
2.7 Adalimumab Monoclonal Antibody Biosimilar Market Competitive Situation and Trends
2.7.1 Adalimumab Monoclonal Antibody Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adalimumab Monoclonal Antibody Biosimilar Players Market Share by Revenue
2.7.3 Global Adalimumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adalimumab Monoclonal Antibody Biosimilar Retrospective Market Scenario by Region
3.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Adalimumab Monoclonal Antibody Biosimilar Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region: 2018-2029
3.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region: 2018-2023
3.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region: 2024-2029
3.3 Global Adalimumab Monoclonal Antibody Biosimilar Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Region: 2024-2029
3.4 North America Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.4.1 North America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.4.3 North America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.5.1 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2029)
4.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2018-2023)
4.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Type (2024-2029)
4.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Adalimumab Monoclonal Antibody Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2029)
5.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2018-2023)
5.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Application (2024-2029)
5.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Adalimumab Monoclonal Antibody Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Cadila Healthcare
6.1.1 Cadila Healthcare Corporation Information
6.1.2 Cadila Healthcare Description and Business Overview
6.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.1.5 Cadila Healthcare Recent Developments/Updates
6.2 Torrent Pharmaceuticals
6.2.1 Torrent Pharmaceuticals Corporation Information
6.2.2 Torrent Pharmaceuticals Description and Business Overview
6.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.2.5 Torrent Pharmaceuticals Recent Developments/Updates
6.3 Amgen
6.3.1 Amgen Corporation Information
6.3.2 Amgen Description and Business Overview
6.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.3.5 Amgen Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Corporation Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Novartis Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Samsung Bioepis
6.6.1 Samsung Bioepis Corporation Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.6.5 Samsung Bioepis Recent Developments/Updates
6.7 Viatris
6.6.1 Viatris Corporation Information
6.6.2 Viatris Description and Business Overview
6.6.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Viatris Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.7.5 Viatris Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Fresenius Kabi
6.9.1 Fresenius Kabi Corporation Information
6.9.2 Fresenius Kabi Description and Business Overview
6.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.9.5 Fresenius Kabi Recent Developments/Updates
6.10 Coherus
6.10.1 Coherus Corporation Information
6.10.2 Coherus Description and Business Overview
6.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Coherus Adalimumab Monoclonal Antibody Biosimilar Product Portfolio
6.10.5 Coherus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab Monoclonal Antibody Biosimilar Industry Chain Analysis
7.2 Adalimumab Monoclonal Antibody Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab Monoclonal Antibody Biosimilar Production Mode & Process
7.4 Adalimumab Monoclonal Antibody Biosimilar Sales and Marketing
7.4.1 Adalimumab Monoclonal Antibody Biosimilar Sales Channels
7.4.2 Adalimumab Monoclonal Antibody Biosimilar Distributors
7.5 Adalimumab Monoclonal Antibody Biosimilar Customers
8 Adalimumab Monoclonal Antibody Biosimilar Market Dynamics
8.1 Adalimumab Monoclonal Antibody Biosimilar Industry Trends
8.2 Adalimumab Monoclonal Antibody Biosimilar Market Drivers
8.3 Adalimumab Monoclonal Antibody Biosimilar Market Challenges
8.4 Adalimumab Monoclonal Antibody Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock
This site is protected by VikingCloud's Trusted Commerce program